Senzime ABSNZZF 68 Quick Ratio is 2.92 as of Mar. 2026, which is 35% below its 10-year median of 4.49. GuruFocus rates SNZZF with a GF Score™ of 68/100 and a GF Value™ of $1.20 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Senzime AB ranks better than 67.13% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Senzime AB's quick ratio for the quarter that ended in Mar. 2026 was 2.92.
Senzime AB has a quick ratio of 2.92. It generally indicates good short-term financial strength.
The historical rank and industry rank for Senzime AB's Quick Ratio or its related term are showing as below:
SNZZF'
s Quick Ratio Range Over the Past 10 Years
Min: 1.7 Med: 4.49 Max: 15.6
Current: 2.92
During the past 13 years, Senzime AB's highest Quick Ratio was 15.60. The lowest was 1.70. And the median was 4.49.
SNZZF's Quick Ratio is ranked better than 67.13% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 1.86
vs SNZZF: 2.92
Senzime AB (OTCPK:SNZZF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Senzime AB Quick Ratio Related Terms
Senzime AB Quick Ratio Historical Data
* Premium members only.
The historical data trend for Senzime AB's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Senzime AB's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senzime AB Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Senzime AB's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Senzime AB's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Senzime AB's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senzime AB (SNZZF) has a Quick Ratio of 2.92 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Senzime AB and its competitors. This is 35% below median its historical median of 4.49. Over the past decade, Senzime AB's Quick Ratio has ranged from 1.70 to 15.60. According to the industry distribution chart, Senzime AB ranks #281 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 32.9%.
Is Senzime AB's Quick Ratio too high?
Senzime AB's current Quick Ratio of 2.92 is 35% below median its 10-year median of 4.49. Over the past 10 years, this metric has ranged from a low of 1.70 to a high of 15.60. The Medical Devices & Instruments industry median Quick Ratio is 1.86. Senzime AB's value of 2.92 is 57% above this industry median. Based on the distribution chart, Senzime AB ranks #281 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Senzime AB has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Senzime AB's Quick Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Senzime AB ranks #281 out of 855 companies for Quick Ratio. This puts Senzime AB in the upper half of its industry. The industry median Quick Ratio is 1.86. Senzime AB's value of 2.92 is 57% above this benchmark. Historically, Senzime AB's own Quick Ratio has ranged from 1.70 to 15.60 over the past decade. While the company's 10-year median is 4.49 vs. the industry median of 1.86, Senzime AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.86, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senzime AB's current Quick Ratio of 2.92 is 57% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Senzime AB and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senzime AB's current Quick Ratio is 2.92, which is 35% below median its own 10-year median of 4.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senzime AB stock overvalued right now?
Based on GuruFocus' analysis, Senzime AB (SNZZF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.20, compared to a current price of $0.48 — trading 60.1% below its estimated fair value. The current Quick Ratio is 2.92, which is 35% below median its 10-year median of 4.49 and 57% above the Medical Devices & Instruments industry median of 1.86. Senzime AB's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Senzime AB (SNZZF), the current Quick Ratio is 2.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Senzime AB (SNZZF) Overvalued in 2026?
Based on GuruFocus' analysis, Senzime AB stock appears to be undervalued.
The current stock price of $0.48 is trading 60.1% below its estimated GF Value™ of $1.20.
GuruFocus considers Senzime AB to be Possible Value Trap.
Key valuation signals for SNZZF:
Quick Ratio: 2.92 (35% below median its 10-year median of 4.49)
GF Value™: $1.20 vs. price of $0.48 (60.1% below fair value)
Industry Position: 57% above the Medical Devices & Instruments median (#281 of 855)
No single metric tells the full story. See the SNZZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Senzime AB is a medical device company developing precision-based patient monitoring solutions for patients undergoing anesthesia. The company develops and markets precision-based monitoring systems for monitoring neuromuscular function and respiration during and after surgery, as well as for intensive care. Its product portfolio includes Next-generation TetraGraph, TetraGraph connectivity, TetraGraph for pediatric, Classic TetraGraph, and ExSpiron. The TetraGraph system is used in thousands of operating rooms internationally in university hospitals, public, private, military, and veterans hospitals. Senzime has direct sales resources in the USA and Germany and collaborates with distributors and licensees in its other main markets.
68GF Score
Get the complete analysis for SNZZF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNZZF has been successfully added to your 
